Traws Pharma blue.png
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024 09:29 ET | Traws Pharma, Inc.
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma blue.png
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
May 07, 2024 08:00 ET | Traws Pharma, Inc.
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Onconova Logo BLUE.jpg
Traws Pharma Announces New Employee Inducement Grants
April 02, 2024 07:15 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in...
Onconova Logo BLUE.jpg
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
April 02, 2024 07:00 ET | Onconova Therapeutics, Inc.
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential...
Onconova Logo BLUE.jpg
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
March 08, 2024 08:00 ET | Onconova Therapeutics, Inc.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Onconova Logo BLUE.jpg
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
December 12, 2023 08:00 ET | Onconova Therapeutics, Inc.
Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings ...
Onconova Logo BLUE.jpg
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
December 08, 2023 16:05 ET | Onconova Therapeutics, Inc.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Onconova Logo BLUE.jpg
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
November 14, 2023 16:05 ET | Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Logo BLUE.jpg
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
November 07, 2023 16:05 ET | Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023